Autoimmune bullous diseases: Ocular manifestations and management

Caroline Laforest, Shyamala C. Huilgol, Robert Casson, Dinesh Selva, Igal Leibovitch

Research output: Contribution to journalReview articlepeer-review

Abstract

The ocular manifestations of autoimmune bullous diseases are common and potentially sight-threatening. Major ophthalmic involvement is most commonly seen in mucous membrane pemphigoid (cicatricial pemphigoid), epidermolysis bullosa acquisita, linear IgA bullous disease, pemphigus vulgaris and paraneoplastic pemphigus. The main pathological process is related to autoimmuneinduced conjunctival inflammation with consequent lid and corneal pathology, which may eventually result in permanent visual loss. Ocular involvement can be asymptomatic. Early detection is aided by careful attention to symptoms and signs of early ophthalmic disease. Ocular disease can be difficult to treat and management usually involves systemic therapy with immunomodulators to control inflammation and prevent progression to irreversible blindness, as well as surgical intervention in advanced disease. Recent advances in treatment, including metho-trexate, mycophenolate mofetil, monoclonal antibodies and topical tacrolimus therapies, have led to promising results.

Original languageEnglish
Pages (from-to)1767-1779
Number of pages13
JournalDrugs
Volume65
Issue number13
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Dive into the research topics of 'Autoimmune bullous diseases: Ocular manifestations and management'. Together they form a unique fingerprint.

Cite this